Summary
To establish the effects of alpha-adrenoceptor blockade on dopamine-induced changes in renal hemodynamics and sodium excretion, dopamine dose-response curves were performed without and with pretreatment with the selective postsynaptic alpha1-adrenoceptor antagonist prazosin in normal volunteers and in patients with renal disease and moderately impaired renal function.
Prazosin (1 mg p. o. every 4 h) in 7 volunteers did not significantly affect baseline values but impaired the response of effective renal plasma flow (ERPF) and filtration fraction (FF) to infusions of dopamine in doses ranging from 0.5 to 8 μg/kg per minute and completely abolished the dopamine-induced increase in sodium excretion. In 7 patients with renal disease and a glomerular filtration rate (GFR) ranging from 38–85 ml/min pretreatment with prazosin did not affect baseline ERPF, GFR or FF or their response to dopamine infusion, but sodium excretion and its response to dopamine infusion were reduced (fractional excretion of sodium at baseline 1.78 without and 0.89 with prazosin pretreatment).
We conclude that alpha1-adrenoceptor blockade with prazosin abolishes the effects of exogenous dopamine on sodium excretion in normal man. Prazosin also impairs the renal vasodilatory action of dopamine. However, the effect on sodium excretion is not directly related to inhibition of dopamine-induced renal vasodilation since in patients with renal disease prazosin also markedly reduces sodium excretion but does not influence the renal hemodynamic effects of dopamine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bateman DN, Hobbs DC, Twomey TM, Stevens EA, Rawlins MD (1979) Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol 16:177–181
Bauer JH, Jones LB, Gaddy P (1984) Effects of prazosin therapy on blood pressure, renal function and body fluid composition. Arch Intern Med 144:1196–1200
DiBona GF (1982) The function of renal nerves. Rev Physiol Biochem Pharmacol 94:75–181
Donker AJM, Hem KG van der, Sluiter WJ, Beekhuis H (1977) A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 20:97–103
Fijter CWH de, Comans EFI, Vries PMJM de, Oe PL, Roos JC, Smit AJ, Streurman O, Donker AJM (1990) The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure. Neth J Med 36:267–278
Goldberg LI (1972) Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 24:1–29
Goodall, McC, Alton H (1968) Metabolism of 3-hydroxytyramine (dopamine) in human subjects. Biochem Pharmacol 17:905–909
Langer SZ, Hicks PE (1984) Alpha-adrenoceptor subtypes in blood vessels: physiology and pharmacology. J Cardiovasc Pharmacol 6:S547-S558
Lee MR (1982) Dopamine and the kidney. Clin Sci 62:439–448
Nahorski SR (1981) Identification and significance of beta-adrenoceptor subtypes. Trends Pharmacol Sci 3:95–98
Osborn JL, Holdaas H, Thames MD, DiBona GF (1983) Renal adrenoceptor mediation of antinatriuretic and renin secretion responses to low frequency renal nerve stimulation in the dog. Circ Res 53:298–305
Pettinger WA, Smyth DD, Umemura S (1985) Renal alpha2-adrenoceptors, their locations and effects on sodium excretion. J Cardiovasc Pharmacol 7:S24-S27
Rand MJ, McCulloch MW, Story DF (1975) Pre-junctional modulation of noradrenergic transmission by noradrenaline, dopamine and acetylcholine. In: Davies DS, Reid JL (eds) Central action of drugs in blood pressure regulation. Pitman Medical, London, pp 94–132
Rogenes PR, Gottschalk CW (1982) Renal function in conscious rats with chronic unilateral renal denervation. Am J Physiol 242:F140-F148
Rubin PC, Blaschke TF (1980) Studies on the clinical pharmacology of prazosin: I. Cardiovascular, catecholamine and endocrine changes following a single dose. Br J Clin Pharmacol 10:23–32
Smit AJ, Meijer S, Wesseling H, Reitsma WD, Donker AJM (1989) Impaired renal hemodynamic but conserved natriuretic response to dopamine in patients with renal disease. Nephron 52:338–346
Smit AJ, Meijer S, Wesseling H, Donker AJM, Reitsma WD (1990) Dissociation of renal hemodynamic and natriuretic effects of dopamine during sulpiride infusion in normal man. Eur J Clin Pharmacol 39:221–226
Smyth DD, Umemura S, Pettinger WA (1986) Renal alpha2-adrenergic receptors multiply and mediate sodium retention after prazosin treatment. Hypertension 8:323–331
Stanaszek WF, Kellerman D, Brogden RN, Romankiewicz JA (1983) Prazosin update: a review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25:339–384
Summers RF (1984) Renal alpha adrenoceptors. Fed Proc 43:2917–2922
Twomey TM, Hobbs DC (1978) Analysis of prazosin in plasma by a sensitive high-performance liquid chromatographic-fluorescence method. J Pharm Sci 67:1468–1469
Wolff PW, Buckalew VM, Strandhoy JW (1984) Renal alpha-1 and alpha-2 adrenoceptor mediated vasoconstriction in dogs: Comparison of phenylephrine, clonidine and guanabenz. J Cardiovasc Pharmacol 6:S793-S798
Zanchetti A (1977) Neural regulation of renin release. Experimental evidence and clinical implications in arterial hypertension. Circulation 56:691–698
Author information
Authors and Affiliations
Additional information
Send offprint requests to A. J. Smit at the above address
Rights and permissions
About this article
Cite this article
Smit, A.J., Meijer, S., Wesseling, H. et al. The effects of alpha-adrenoceptor blockade on dopamine-induced renal vasodilation and natriuresis. Naunyn-Schmiedeberg's Arch Pharmacol 343, 143–148 (1991). https://doi.org/10.1007/BF00168601
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00168601